Trials / Recruiting
RecruitingNCT06461156
A Study of HS-10504 in Patients With Advanced or Metastatic Non-Small-Cell Lung Cancer(NSCLC)
A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of HS-10504 in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC）
- Status
- Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 230 (estimated)
- Sponsor
- Jiangsu Hansoh Pharmaceutical Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
HS-10504 is a fourth-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor targeting EGFR C797S mutation. This study will evaluate the safety, tolerability, pharmacokinetics and efficacy of HS-10504 in Chinese locally advanced or metastatic NSCLC.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | HS-10504 | HS-10504 will be administered orally once daily in a continuous regimen. Participants will continue treatment until experiencing objective disease progression or meeting other protocol-specified criteria for discontinuation of study treatment. |
Timeline
- Start date
- 2025-07-22
- Primary completion
- 2026-12-31
- Completion
- 2027-03-31
- First posted
- 2024-06-14
- Last updated
- 2025-09-17
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06461156. Inclusion in this directory is not an endorsement.